Alternatives to AN2 Therapeutics

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Global biopharmaceutical company focused on oncology and neuroscience treatments.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

A global leader in clinical pharmacology and bioanalytical sciences.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Pioneering vision restoration therapies for severe retinal degenerations.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on oncology drug discovery.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing first-in-class oral therapy for BK polyomavirus infections.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Advancing targeted alpha therapies.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Biotechnology company developing novel protein-based antimicrobial therapeutics.

Pioneering next-generation bispecific ADCs for cancer treatment.

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Global supplier of life science research tools, including antibodies, reagents, and assays.

A vertically-integrated procurement platform for the life sciences industry.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A biotechnology company developing genetic therapies for rare disorders.

AI-powered knowledge discovery for life sciences.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing highly targeted, small molecule medicines.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

AI-powered antibody discovery platform.

Advancing next-generation mRNA medicines.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Clinical-stage biotech company targeting RNA modifications for novel cancer therapies.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Unlocking industrial-scale RNA-seq for primary drug screening and toxicology.